-
Upadacitinib, sold
under the
brand name Rinvoq, is a
medication used for the
treatment of
rheumatoid arthritis,
psoriatic arthritis,
atopic dermatitis...
-
Administration (FDA)
requires a
boxed warning for tofacitinib, baricitinib, and
upadacitinib to
include information about the
risks of
serious heart-related events...
-
available on the market. The JAK1
inhibitors tofacitinib (Xeljanz) and
upadacitinib (Rinvoq) are
approved for the use in
active psoriatic arthritis. The...
- Mavyret/Maviret (glecaprevir/pibrentasvir)
Skyrizi (risankizumab)
Rinvoq (
upadacitinib)
Revenue US$54.32
billion (2023)
Operating income US$12.76
billion (2023)...
- issues. Some JAK
inhibitors such as abrocitinib,
trade name Cibinqo, and
upadacitinib,
trade name Rinvoq, have been
approved in the US for the
treatment of...
- with
myelofibrosis and vitiligo.
Examples are tofacitinib, baricitinib,
upadacitinib and filgotinib. In 2014
researchers discovered that oral JAK inhibitors...
- certolizumab, vedolizumab, ustekinumab, natalizumab,risankizumab-rzaa, and
upadacitinib Hydrocortisone should be used in
severe attacks of Crohn's disease. Biological...
-
Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib)
Upadacitinib JAK2
Atiprimod AZD-1480
Baricitinib CHZ868
Cucurbitacin I (elatericin...
-
Ponesimod L04AE05
Etrasimod L04AF01
Tofacitinib L04AF02
Baricitinib L04AF03
Upadacitinib L04AF04
Filgotinib L04AF05
Itacitinib L04AF06
Peficitinib L04AF07 Deucravacitinib...
- immunosuppressants:
ciclosporin (cyclosporin), tacrolimus, sirolimus,
upadacitinib; many chemotherapeutics: docetaxel, tamoxifen, pa****axel, cyclophosphamide...
